Replimune Counts Accounts, Not Patients, For Its Tudrakev Launch — And Offers No Revenue Guidance

Executives cited about 20 accounts on formulary and a $450,000 list price per course, with no first product revenue until next quarter.

Share
Replimune Counts Accounts, Not Patients, For Its Tudrakev Launch — And Offers No Revenue Guidance

Replimune, the clinical-stage cancer biotech behind the newly launched melanoma therapy Tudrakev, will track accounts rather than patients and will give no revenue guidance, executives said on the company's fiscal second-quarter earnings call Wednesday. Chief Financial Officer Emily Hill said the company recorded no product revenue in the quarter because first commercial shipments came in early October.

Why patient counts are off the table

Hill said Tudrakev dosing runs about one milliliter per centimeter used for patients, so

The launch funnel

Chief Commercial Officer Michelle DiNapoli said the company has engaged more than 70% of its initial 200 target accounts. About 20 accounts have put the drug on formulary, and as of Friday over 15 institutions had written one or more prescriptions, in under 20 business days.

She named Moffitt and Memorial Sloan Kettering among high-volume centers that moved quickly. DiNapoli said that by the end of the year the number of accounts initiating patients could roughly double, and that the company holds 23 account management positions. NCCN guidelines list Tudrakev as a Category 2A recommendation, and she said Medicare coverage is in place. A permanent J-code, a billing code, is anticipated by April 2027.

CEO Sushil Patel said there are about 10,000 addressable patients in the US and more than a year of inventory made at the company's own plant.

Price, cash and unanswered volume

Tudrakev lists at $450,000 per course before customary rebates and discounts, Hill said. The actual cost varies with tumor burden and cycles, and patients may receive eight or more.

The quarter's net loss was $57.1 million, against $69.8 million in the first fiscal quarter. Research and development spending was $34.4 million, down from $49.3 million, while selling, general and administrative costs rose to $21.9 million from $19 million as the company built its commercial team. Cash stood at $307.8 million, including $141 million in net proceeds from an August offering, and management expects that to fund operations for more than 12 months.

An analyst at Piper Sandler asked how tumor burden compares with the IGNITE trial. Patel said it was "a little too early" to discuss price or volume. Asked by an analyst at Cantor Fitzgerald about deep versus superficial injections, Patel said IGNITE showed deep injections such as lung and liver tended to use higher volume.

Hill said the company will update formulary and first-script counts, and will share average-volume insight once a patient cohort completes eight or more cycles.

Sources

More on Replimune Group

All Replimune Group (REPL) coverage →